Bright Minds Biosciences Inc.
NASDAQ: DRUG0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ian McDonald
- Employees
- 26
- Headquarters
- New York, Canada
- IPO year
- 2021
- Market cap
- $514.0M
- Website
- https://brightmindsbio.com
Loading DRUG…
Loading profile data…Frequently asked questions about DRUG
What does Bright Minds Biosciences Inc. (DRUG) do?
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclose...
Where does DRUG trade?
Bright Minds Biosciences Inc. (DRUG) trades on the NASDAQ.
What sector is DRUG in?
Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bright Minds Biosciences Inc.?
Ian McDonald is the chief executive officer of Bright Minds Biosciences Inc. (DRUG).
Where is Bright Minds Biosciences Inc. headquartered?
Bright Minds Biosciences Inc. is headquartered in Canada.
Does DRUG pay a dividend?
Bright Minds Biosciences Inc. (DRUG) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DRUG go public?
Bright Minds Biosciences Inc. (DRUG) completed its initial public offering in 2021.